| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| Targets |
NADase targets nicotinamide adenine dinucleotide (NAD+), a critical coenzyme involved in cellular redox reactions and energy metabolism. By hydrolyzing NAD+ into nicotinamide mononucleotide (NMN) and ADP-ribose, NADase regulates intracellular NAD+ homeostasis. The enzyme is a promising target for research on autoimmune diseases and aging-related disorders.
|
|---|---|
| ln Vitro |
NADase enzymatic activity is measured by its ability to hydrolyze β-NAD to nicotinamide and ADP-ribose. One unit is defined as the amount of enzyme that hydrolyzes 1.0 µmole of β-NAD per minute at pH 7.3 and 37°C. The enzyme is active across a broad pH range of 3.0-9.0. Nicotinamide acts as an inhibitor of NADase activity.
|
| ln Vivo |
In vivo, NADase is involved in regulating intracellular NAD+ levels, which impacts cellular energy metabolism and signaling pathways. It is studied in the context of autoimmune diseases (e.g., systemic sclerosis, systemic lupus erythematosus) and aging-related disorders. NADase from porcine brain has been used to investigate histidine and related compounds in ADP-ribosylation reactions.
|
| Enzyme Assay |
In vitro enzyme assays for NADase: the enzyme is dissolved in water (1 mg/mL) and diluted with 100 mM potassium phosphate buffer (pH 7.3 at 37°C) before use. β-NAD is used as substrate, and the reaction is monitored by measuring the production of nicotinamide or ADP-ribose using spectrophotometric or HPLC methods. Nicotinamide inhibition studies are performed using 0.1 M nicotinamide.
|
| Cell Assay |
Cellular assays for NADase: cells are treated with NADase or NADase inhibitors, and intracellular NAD+ levels are measured using enzymatic cycling assays or LC-MS/MS. Cell viability is assessed using standard cytotoxicity assays. The role of NADase in cellular NAD+ homeostasis is studied in various cell lines including immune cells and fibroblasts.
|
| Animal Protocol |
In vivo animal studies for NADase: animal models of autoimmune diseases (e.g., systemic lupus erythematosus in MRL/lpr mice) are used to study NADase inhibition. NADase activity and NAD+ levels are measured in tissues. The effects of NADase modulation on disease progression, inflammation markers, and immune cell function are evaluated. Pharmacological inhibitors of NADase are tested for therapeutic efficacy.
|
| ADME/Pharmacokinetics |
NADase is an enzyme preparation available as an acetone-dried powder from porcine brain. Pharmacokinetic properties of NADase as a therapeutic agent are not applicable, as it is an enzyme used in research applications. It is stable when stored at recommended conditions and is typically prepared fresh before use in enzymatic assays.
|
| Toxicity/Toxicokinetics |
NADase as an enzyme reagent is generally considered safe for laboratory use. No significant toxicity has been reported. Nicotinamide, a known NADase inhibitor, is used in some assays. Standard laboratory safety precautions should be followed when handling the enzyme preparation. The product is not intended for human therapeutic use.
|
| Additional Infomation |
NADase is a research reagent used in biochemical and pharmacological studies of NAD+ metabolism. It is used to investigate the role of NAD+ hydrolysis in autoimmune diseases and aging. The enzyme is available from various suppliers as a purified preparation from porcine brain. No clinical applications or FDA approvals have been reported.
|
| CAS # |
9032-65-9
|
|---|---|
| Appearance |
Off-white to light yellow solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
